Awakn Life Sciences Corp. AWKN AWKNF, a biotech company developing psychedelic medicines for addiction, has received approval to launch a human study looking into the effects of ketamine in gambling addiction.
The early-stage study will analyze if ketamine administration can modify reward memories associated with gambling, and if successful, will serve as the basis for possible clinical trials using the same method in improving gambling addiction.
While Awakn has begun recruiting human participants, this study is not a clinical trial, explained Prof. Celia Morgan, Awakn’s head of ketamine-assisted psychotherapy, in an interview with Benzinga.
“It’s a mechanistic study, where we’re looking at modulating memory,” she added. “We’re not looking at clinical outcomes, so we’re not looking at changes in gambling severity as an outcome of this. We’re simply looking to see how strongly people react to gambling queues.”
Treating Addiction By Modifying Memories With Ketamine
Through this study, the research team is trying to understand if, by blocking the body’s NMDA receptors, ketamine can block the reconsolidation of memories associated with gambling behaviour.
Memory reconsolidation is a process by which previously consolidated memories are recalled and actively consolidated. This process serves to maintain, strengthen and modify memories stored in long-term memory. By tapping into this process, ketamine could modify fixed memories that trigger compulsive behaviour.
“Recent scientific evidence has shown that when you reactivate a memory, this one is not only able to be updated but also weakened and potentially destroyed if you block a biological process known as reconsolidation, which agents like ketamine can do,” Morgan said.
The team will try out a new paradigm in which they will ask gamblers to reactivate a gambling memory and then administer ketamine within that window.
If the strong memories that lead to compulsive behaviour can be weakened, ketamine could have a very valuable therapeutic effect in the treatment of addiction and behavioural disorders, by breaking the reward cycle associated with initial memories.
Photo: Michał Parzuchowski on Unsplash
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!